Business Description
Formycon AG
ISIN : DE000A1EWVY8
Total Employee Number:
203Description
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.2 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -10.77 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.16 | |||||
Beneish M-Score | -2.09 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -6.6 | |||||
3-Year FCF Growth Rate | 9 | |||||
3-Year Book Growth Rate | -1.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 40.65 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.33 | |||||
Quick Ratio | 2.3 | |||||
Cash Ratio | 1.29 | |||||
Days Inventory | 10.38 | |||||
Days Sales Outstanding | 146.72 | |||||
Days Payable | 203.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.3 | |||||
Shareholder Yield % | 0.2 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 8.04 | |||||
Operating Margin % | -68.58 | |||||
Net Margin % | -145.46 | |||||
EBITDA Margin % | -2 | |||||
FCF Margin % | -99.17 | |||||
OCF Margin % | 24.24 | |||||
ROE % | -15.29 | |||||
ROA % | -8.61 | |||||
ROIC % | -3.2 | |||||
3-Year ROIIC % | 1.99 | |||||
ROC (Joel Greenblatt) % | -467.32 | |||||
ROCE % | -12.33 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 272.84 | |||||
PS Ratio | 7.71 | |||||
PB Ratio | 0.85 | |||||
Price-to-Operating-Cash-Flow | 31.55 | |||||
EV-to-EBIT | -3 | |||||
EV-to-EBITDA | -294.92 | |||||
EV-to-Revenue | 5.88 | |||||
EV-to-FCF | -6.32 | |||||
Price-to-GF-Value | 0.52 | |||||
Price-to-Projected-FCF | 6.55 | |||||
Price-to-Median-PS-Value | 0.7 | |||||
Earnings Yield (Greenblatt) % | -33.36 | |||||
FCF Yield % | -13.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Formycon AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 44.476 | ||
| EPS (TTM) (€) | -3.66 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -54.52 | ||
| 3-Year Sortino Ratio | -3.46 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 63.3 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 63.3 - 63.3 | ||
| Shares Outstanding (Mil) | 17.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Formycon AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Formycon AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Formycon AG Frequently Asked Questions
What is Formycon AG(CHIX:FYBd)'s stock price today?
The current price of CHIX:FYBd is €63.30. The 52 week high of CHIX:FYBd is €63.30 and 52 week low is €63.30.
When is next earnings date of Formycon AG(CHIX:FYBd)?
The next earnings date of Formycon AG(CHIX:FYBd) is .
Does Formycon AG(CHIX:FYBd) pay dividends? If so, how much?
Formycon AG(CHIX:FYBd) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Formycon AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers